Unique ID issued by UMIN | UMIN000022212 |
---|---|
Receipt number | R000025586 |
Scientific Title | A clinical trial of the effects of topical steroid cream (PVA-N11) on atopic dermatitis. |
Date of disclosure of the study information | 2016/05/06 |
Last modified on | 2018/11/13 07:27:55 |
A clinical trial of the effects of topical steroid cream (PVA-N11) on atopic dermatitis.
A clinical trial of the effects of topical steroid cream (PVA-N11) on atopic dermatitis.
A clinical trial of the effects of topical steroid cream (PVA-N11) on atopic dermatitis.
A clinical trial of the effects of topical steroid cream (PVA-N11) on atopic dermatitis.
Japan |
Atopic dermatitis
Dermatology |
Others
NO
To confirm the clinical efficacy and safety of topical steroid cream (PVA-N11) in the treatment of atopic dermatitis.
Safety,Efficacy
Severity classification (simple method) of atopic dermatitis developed by the advisory committee of atopic dermatitis severity classification of Japanese Dermatological Association at test site (both arms) before and after the two-week application.
1) Transepidermal water loss, water content of the stratum corneum, erythema and pigmentation, and skin surface topography at test site (both arms) before and after the one- and the two-week application.
2) Questionnaires for QOL assessment in atopic dermatitis before and after the one- and the two-week application, and two weeks after the end of application.
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Active
No need to know
2
Treatment
Medicine |
Apply topical steroid cream (PVA-N11) twice a day for 2 weeks.
Apply active comparator twice a day for 2 weeks.
16 | years-old | <= |
49 | years-old | >= |
Male and Female
1) Patients with atopic dermatitis.
2) Patients with mild or moderate rash on test site (both arms).
1) Patients with severe skin disorders on test site (both arms) and deemed inappropriate to participate in this study by the principal investigator or sub-investigators.
2) Patients with any complications which affect the results of this study.
3) Patients who might use any external use medicines, anti-allergy drugs, or immunosuppressants.
4) Pregnant or lactating patients. Patients with suspicion of pregnancy.
5) Patients deemed inappropriate to participate in this study by the principal investigator or sub-investigators.
36
1st name | |
Middle name | |
Last name | Masatoshi Abe |
Sapporo Dermatology Clinic
Deputy Chief of Clinic
H&B Plaza Bldg. 5F, 1-1, Minami 3-jo Nishi 2-chome, Chuo-ku, Sapporo, 060-0063, JAPAN
011-221-8807
m.abe@dermalabo.co.jp
1st name | |
Middle name | |
Last name | Yukiyoshi Katsumata |
Exam CO.,LTD
DermaLabo
Kogin Bldg. 5F, 2, Kita 1-jo Nishi 5-chome, Chuo-ku, Sapporo, 060-0001, JAPAN
011-205-0781
katsumata-y@ekusamu.co.jp
Exam CO.,LTD
Kao Corporation
Profit organization
NO
株式会社エクサムデルマラボ(北海道)
2016 | Year | 05 | Month | 06 | Day |
Unpublished
Completed
2016 | Year | 04 | Month | 26 | Day |
2016 | Year | 05 | Month | 09 | Day |
2016 | Year | 05 | Month | 05 | Day |
2018 | Year | 11 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025586